Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here’s What Hedge Funds Think About Acceleron Pharma Inc (XLRN)

The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or less stagnant Europe, weighed heavily on the minds of investors. Both the S&P 500 and Russell 2000 sank as a result, with the Russell 2000, which is composed of smaller companies, being hit especially hard. This was primarily due to hedge funds, which are big supporters of small-cap stocks, pulling some of their capital out of the volatile markets during this time. Let’s look at how this market volatility affected the sentiment of hedge funds towards Acceleron Pharma Inc (NASDAQ:XLRN), and what that likely means for the prospects of the company and its stock.

Acceleron Pharma Inc (NASDAQ:XLRN) investors should be aware of a decrease in hedge fund sentiment in recent months. Our calculations also showed that XLRN isn’t among the 30 most popular stocks among hedge funds.

Why do we pay any attention at all to hedge fund sentiment? Our research has shown that hedge funds’ large-cap stock picks indeed failed to beat the market between 1999 and 2016. However, we were able to identify in advance a select group of hedge fund holdings that outperformed the market by 32 percentage points since May 2014 through March 12, 2019 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that’ll significantly underperform the market. We have been tracking and sharing the list of these stocks since February 2017 and they lost 27.5% through March 12, 2019. That’s why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to.

James Flynn Deerfield Management

We’re going to take a glance at the latest hedge fund action regarding Acceleron Pharma Inc (NASDAQ:XLRN).

What does the smart money think about Acceleron Pharma Inc (NASDAQ:XLRN)?

Heading into the first quarter of 2019, a total of 19 of the hedge funds tracked by Insider Monkey were long this stock, a change of -30% from the previous quarter. By comparison, 22 hedge funds held shares or bullish call options in XLRN a year ago. With hedge funds’ capital changing hands, there exists a select group of noteworthy hedge fund managers who were increasing their stakes considerably (or already accumulated large positions).

XLRN_apr2019

According to Insider Monkey’s hedge fund database, Thomas Steyer’s Farallon Capital has the largest position in Acceleron Pharma Inc (NASDAQ:XLRN), worth close to $91.5 million, comprising 0.8% of its total 13F portfolio. The second largest stake is held by James E. Flynn of Deerfield Management, with a $60.4 million position; 2.4% of its 13F portfolio is allocated to the stock. Remaining professional money managers that hold long positions include Jeffrey Jay and David Kroin’s Great Point Partners, Joseph Edelman’s Perceptive Advisors and Steve Cohen’s Point72 Asset Management.

Because Acceleron Pharma Inc (NASDAQ:XLRN) has witnessed a decline in interest from hedge fund managers, logic holds that there lies a certain “tier” of funds that elected to cut their full holdings heading into Q3. It’s worth mentioning that Lei Zhang’s Hillhouse Capital Management cut the largest position of all the hedgies tracked by Insider Monkey, comprising an estimated $46.6 million in stock, and Gavin Saitowitz and Cisco J. del Valle’s Springbok Capital was right behind this move, as the fund cut about $1.3 million worth. These transactions are interesting, as aggregate hedge fund interest fell by 8 funds heading into Q3.

Let’s check out hedge fund activity in other stocks similar to Acceleron Pharma Inc (NASDAQ:XLRN). We will take a look at Brookfield Business Partners L.P. (NYSE:BBU), Albany International Corp. (NYSE:AIN), PQ Group Holdings Inc. (NYSE:PQG), and Franklin Electric Co., Inc. (NASDAQ:FELE). This group of stocks’ market valuations are similar to XLRN’s market valuation.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
BBU 4 15907 -2
AIN 11 63419 -2
PQG 4 64147 -5
FELE 9 200565 -1
Average 7 86010 -2.5

View table here if you experience formatting issues.

As you can see these stocks had an average of 7 hedge funds with bullish positions and the average amount invested in these stocks was $86 million. That figure was $332 million in XLRN’s case. Albany International Corp. (NYSE:AIN) is the most popular stock in this table. On the other hand Brookfield Business Partners L.P. (NYSE:BBU) is the least popular one with only 4 bullish hedge fund positions. Compared to these stocks Acceleron Pharma Inc (NASDAQ:XLRN) is more popular among hedge funds. Our calculations showed that top 15 most popular stocks) among hedge funds returned 24.2% through April 22nd and outperformed the S&P 500 ETF (SPY) by more than 7 percentage points. Unfortunately XLRN wasn’t nearly as popular as these 15 stock and hedge funds that were betting on XLRN were disappointed as the stock returned -8% and underperformed the market. If you are interested in investing in large cap stocks with huge upside potential, you should check out the top 15 most popular stocks) among hedge funds as 13 of these stocks already outperformed the market this year.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...